Study links microplastics with human health problems – but there’s still a lot we don’t know 
Elon Musk Announces Tesla Job Cuts; Key Executives Drew Baglino and Rohan Patel to Step Down 
Oil and gas lobbyists have deep pockets and access to politicians, but an EU ban could be in the pipeline 
Lawyers are rapidly embracing AI 
Why China’s economy has hit a wall 
Narendra Modi’s economy isn’t booming for India’s unemployed youth 
General practice is in crisis in the UK – and it’s failing the people who need it most 
Introduction of Green License Plates in S, Korea Pull Down Sales of Porsche, Rolls Royce, Bentley 
PepsiCo Issues Recall for Schweppes Ginger Ale Over Sugar Content 
BMW Korea's Investment in S. Korean Suppliers of ₩6.63 Trillion Surpasses its Annual Revenue in the Country 
HMM Announces Major Fleet Expansion to Boost Global Competitiveness 
Some women’s breasts can’t make enough milk, and the effects can be devastating 
SK on, Siemens Partner to Build Smart Factory System for Battery Plants 
Could ADHD drugs reduce the risk of early death? Unpacking the findings from a new Swedish study 
Snakebites: we thought we’d created a winning new antivenom but then it flopped. Why that turned out to be a good thing 
Xiaomi SU7 Offers Limited-Time Modification Service; Delivery Delays Extend to Six Months 
Bristol Myers Squibb has sued AstraZeneca for its antibody-based cancer treatment Imjudo, which it says infringes its patents for its drug Yervoy
According to Bristol Myer, Imjudo fights cancer in the same way as Yervoy.
Bristol Myers has previously sued AstraZeneca for patent infringement over the latter’s other cancer drug, Imfinzi.
AstraZeneca said it is aware of the complaint and will respond to it "at the appropriate time."
The FDA has also approved the immunotherapy Yervoy for the treatment of kidney, lung, colorectal, and other cancers. The FDA initially approved Yervoy in 2011 to treat melanoma.
In 2021, Bristol Myers sold over $2 billion worth of Yervoy.
AstraZeneca’s Imjudo was given FDA approval last year to be used in conjunction with Imfinzi to treat liver and lung cancer.
In the second lawsuit, Bristol Myers claimed that AstraZeneca had violated two patents on the use of antibodies to treat cancer and strengthen a patient's immune system.
Bristol Myers insists that AstraZeneca was aware of the patents, being on notice due to licensing discussions and the Imfinzi lawsuit.
The lawsuit seeks an unspecified amount of money for damages.
